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ABSTRACT 
Background:  
Dialysis patients are at a higher risk of bleeding after PCI; however, due to their exclusion from 
randomized clinical trials, the optimal antithrombotic regimen for this population remains 
unknown. We sought to evaluate the comparative safety and effectiveness of bivalirudin 
monotherapy versus unfractionated heparin (UFH) monotherapy in dialysis patients undergoing 
percutaneous coronary intervention (PCI). 
 
Methods:  
We included dialysis patients who underwent PCI in a multicenter registry between January 
2010 and September 2015 at 47 Michigan hospitals. We compared in-hospital outcomes between 
bivalirudin versus UFH; excluding those treated with glycoprotein IIb/IIIa inhibitors. Optimal 
full matching was used to account for the non-random use of these drugs. 
 
Results:  
Of 177,963 patients who underwent PCI, 4,303 (2.4%) were on dialysis. Among those, 1,257 
(29.2%) received bivalirudin monotherapy and 2,112 (49.1%) received UFH monotherapy. 
Patients treated with bivalirudin had fewer comorbidities. After matching, there were no 
significant differences in outcomes between those who received bivalirudin versus UFH: 
bleeding (adjusted odds ratio: 0.67; 95% confidence interval: 0.41–1.07; P=0.093); major 
bleeding (0.81; 0.19–3.50; P=0.77); transfusion (1.01; 0.77–1.33; P=0.96); repeat PCI (0.57; 
0.14–2.24; P=0.42); stent thrombosis (0.56; 0.05–5.83; P=0.63); and death (0.84; 0.46–1.51; 
P=0.55).  
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Conclusions:  
We found no significant differences in in-hospital outcomes between bivalirudin and UFH 
monotherapy among dialysis patients undergoing PCI. Randomized clinical trials are needed to 
determine the optimal anticoagulant regimen for this population. 
  
Word coun : 227 words (max 250 words) 
Keywords: Percutaneous coronary intervention; chronic kidney disease; anticoagulant; dialysis; 
outcomes. 
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ABBREVIATIONS 
CKD = chronic kidney disease 
PCI = percutaneous coronary intervention 
UFH = unfractionated heparin 
GPI = glycoprotein IIb/IIIa inhibitor 
BMC2 = Blue Cross Blue Shield of Michigan Cardiovascular Consortium 
NCDR = National Cardiovascular Data Registry 
CAD = coronary artery disease 
STEMI = ST-segment elevation myocardial infarction 
NSTEMI = non-ST-segment elevation myocardial infarction 
IABP = intra-aortic balloon pump 
aOR = adjusted odds ratio 
CI = confidence interval 
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INTRODUCTION 
 Patients on dialysis suffer death from cardiovascular causes at rates five to 30 times 
higher than the general population, making cardiovascular disease the leading cause of death in 
patients with end-stage renal disease (1). Chronic kidney disease (CKD) is associated with an 
increased risk of both bleeding and thrombosis due to multiple hemostatic perturbations (2,3). 
Furthermore, these patients experience increased rates of bleeding and reduced survival after 
percutaneous coronary intervention (PCI) when compared with patients without CKD (4-8). In 
fact, progressively worse outcomes after PCI are associated with increasingly severe stages of 
CKD, with the poorest outcomes occurring in patients on dialysis (5).  
 Despite this increased risk, patients on dialysis are underrepresented in, or excluded from 
important cardiovascular randomized controlled trials, resulting in a remarkable dearth of 
evidence to inform treatment in this high-risk population (9,10). Specifically, patients on dialysis 
have been underrepresented or excluded from trials evaluating the safety and effectiveness of 
unfractionated heparin (UFH) compared with bivalirudin (11-18). Many of these clinical trials 
demonstrated a reduction in bleeding complications without a significant difference in ischemic 
outcomes in patients treated with bivalirudin compared with UFH with or without glycoprotein 
IIb/IIIa inhibitors (GPIs) (11-16). Recently, studies have shown similar safety and effectiveness 
between bivalirudin monotherapy and UFH monotherapy in patients undergoing PCI, reigniting 
interest in UFH monotherapy as a more cost-effective treatment strategy (19,20). 
To our knowledge, there are few studies assessing the use of antithrombotic medications 
in dialysis patients undergoing PCI (21,22). Given the paucity of evidence, we sought to assess 
the comparative safety and effectiveness of bivalirudin monotherapy versus UFH monotherapy 
in dialysis patients undergoing PCI using a multicenter registry in the state of Michigan.  
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METHODS 
 
Study population 
We performed a retrospective analysis on data collected by the Blue Cross Blue Shield of 
Michigan Cardiovascular Consortium (BMC2), a regional registry of all patients undergoing PCI 
in the state of Michigan. A more detailed description of the registry, including data collection 
and auditing practices, has been described previously (23,24). Briefly, this is a prospective, 
multicenter, statewide registry of patients undergoing PCI at any non-federal hospital in 
Michigan. For the current study, we evaluated consecutive patients undergoing PCI between 
January 2010 and September 2015 at 47 hospitals. 
 
Study Groups 
We initially divided patients into two groups, those on dialysis and not on dialysis prior 
to PCI. Patients were considered to be on dialysis if they were undergoing either hemodialysis or 
peritoneal dialysis on an ongoing basis because of renal failure prior to PCI. To compare the 
safety and effectiveness of procedural bivalirudin and UFH, we stratified patients on dialysis by 
administration of these two drugs. The BMC2 PCI registry does not routinely collect the dosages 
of bivalirudin or UFH administered during PCI.  
We excluded patients who received procedural or pre-procedural low molecular weight 
heparin and/or fondaparinux as well as patients who had no recorded anticoagulant administered 
in the procedural time period. We also excluded patients who received a concomitant GPI, since 
GPI use is frequently restricted to higher risk anatomic subsets, or for bailout use secondary to 
suboptimal procedural results or complications. Of note, patients receiving procedural 
bivalirudin may have received pre-procedural UFH. Furthermore, a small fraction of patients 
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receiving procedural bivalirudin also had documented administration of procedural UFH (e.g. 
UFH is sometimes used during radial access cases). The impact of this subgroup on in-hospital 
outcomes was assessed in a sensitivity analysis excluding these patients. 
 
Study outcomes 
 All primary outcomes were measured during the incident hospitalization when PCI was 
performed. In-hospital outcomes included bleeding, presumed major bleeding, the need for 
transfusion, repeat PCI, stent thrombosis, and death due to any cause. Stent thrombosis was 
defined as thrombosis at the site of original stent placement demonstrated on repeat angiography. 
Repeat PCI was defined as repeat intervention during the incident hospitalization on the lesion 
that was initially treated. Bleeding, defined as per the National Cardiovascular Data Registry 
(NCDR), included an event within 72 hours of PCI that was associated with any of the 
following: a drop in hemoglobin ≥3 g/dL; transfusion of whole blood or packed red blood cells; 
an intervention or surgery at the site of bleeding to reverse, stop, or correct the bleeding (25). 
The need for transfusion was defined as the receipt of ≥1 unit of red blood cell or whole blood 
transfusion after PCI. Presumed major bleeding was defined as a decrease in baseline 
hemoglobin by >5 g/dL.  
 
Statistical analysis 
 Propensity scores were estimated using logistic regression models adjusting for baseline 
patient clinical and demographic variables (supplemental table 1). Optimal full matching was 
used to create matched patient strata constructed of patients generally similar in terms of baseline 
characteristics containing varying numbers of patients with (cases) and without (controls) the 
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covariate of interest (bivalirudin or UFH). As opposed to greedy matching, full matching allows 
treatment group members to share a control group member as long as it reduces the average 
distance between matches (26,27). Exact matching was required on coronary artery disease 
(CAD) presentation (ST-segment elevation myocardial infarction [STEMI], non-ST-segment 
elevation myocardial infarction [NSTEMI], unstable angina, stable angina, or other), race (white 
vs. non-white), cardiogenic shock within 24 hours prior to or at the start of PCI, use of an intra-
aortic balloon pump (IABP) or other mechanical ventricular support devices, and pre-procedural 
cardiac arrest. Stratified standardized differences using full match strata were used to assess the 
adequacy of the match in terms of covariate balance, with a threshold of 10% used to identify 
cases of substantial residual imbalance. Reported outcome rates were weighted by full match 
strata, and conditional logistic regression models accounting for matched patient strata were 
utilized to assess for independent association between procedural use of bivalirudin and UFH, 
and clinical outcomes. A similar full matching technique was used for the sensitivity analysis. 
All analyses were performed using R version 3.2.1 (28). 
Page 8 of 72
Catheterization and Cardiovascular Interventions
Catheterization and Cardiovascular Interventions
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
8 
RESULTS 
Baseline characteristics 
 A total of 177,963 PCIs were performed between January 2010 and September 2015, of 
which 4,303 (2.4%) were on dialysis patients. The baseline characteristics of patients stratified 
by dialysis use are shown in Table 1. Generally, patients on dialysis had more comorbid 
conditions and experienced significantly worse outcomes after PCI, including increased rates of 
blood transfusions (11.9% vs. 2.7%; P < 0.001), NCDR bleeding (4.4% vs. 2.8%; P < 0.001), 
and death (3.5% vs. 1.5%; P < 0.001). Notably, patients on dialysis less frequently experienced 
major bleeding compared with patients not on dialysis (0.6% vs. 1.2%; P < 0.001).  
 Of the 4,303 patients on dialysis who underwent PCI, 109 (2.5%) received low molecular 
weight heparin, 13 (0.3%) received fondaparinux, 614 (14.3%) received a GPI, and 215 (5.0%) 
had no recor ed procedural anticoagulant. A total of 934 (2.3%) patients met at least one 
exclusion criteria, leaving 3,369 patients in the final cohort, of which 1,257 received bivalirudin 
monotherapy and 2,112 received UFH monotherapy. Patients receiving bivalirudin were more 
frequently white (73.3% vs. 56.7%; P < 0.001) and had fewer comorbid conditions (Table 2). 
They were also less likely to experience pre-procedural cardiogenic shock (1.7% vs. 2.9%, P = 
0.026), receive IABP support (1.5% vs. 3.1%, P = 0.003) or mechanical ventricular support 
(0.8% vs. 2.8%, P < 0.001) (Table 2).  Prior to matching, patients treated with bivalirudin 
monotherapy had lower rates of transfusion (8.7% vs. 11.9%; P = 0.003), bleeding (2.7% vs 
4.1%; P = 0.038), and in-hospital mortality (2.2% vs 3.4%; P = 0.051) after PCI compared with 
those treated with UFH monotherapy (Figure 1). 
Outcomes 
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After optimal full matching, the adjusted absolute standardized difference was <10% on 
all matched variables (Figure 2) with generally similar baseline characteristics within matched 
strata (Table 2). There were no significant differences in outcomes after adjusting for matched 
strata between patients treated with bivalirudin compared with UFH: bleeding (adjusted odds 
ratio [aOR] 0.67; 95% confidence interval [CI] 0.41–1.07; P=0.093); major bleeding (aOR 0.81; 
95% CI 0.19–3.50; P=0.77); transfusion (aOR 1.01; 95% CI 0.77–1.33; P=0.96); repeat PCI 
(aOR 0.57; 95% CI 0.14–2.24; P=0.42); stent thrombosis (aOR 0.56; 95% CI 0.05–5.83; 
P=0.63); and death (aOR 0.84; 95% CI 0.46–1.51; P=0.55) (Figure 3). 
After matching, patients treated with bivalirudin monotherapy more frequently underwent 
femoral access PCI (89.9%) compared with UFH monotherapy (85.8%; ASD 13.0%; P=0.002; 
Table 2). Due to this imbalance, we evaluated whether bivalirudin was significantly associated 
with vascular access site after adjusting for clinical factors. We found that bivalirudin 
monotherapy was significantly associated with a reduced likelihood of radial access (aOR 0.71; 
95% CI: 0.56–0.91; P=0.007). We then conducted a stratified analysis of bivalirudin 
monotherapy (n=1,144) versus UFH monotherapy (n=1,869) among patients who underwent 
femoral access PCI. Consistent with the overall findings, we found no significant differences in 
all studied outcomes including bleeding (aOR 0.63; 95% CI 0.38–1.04; P=0.073), major bleeding 
(aOR 1.06; 95% CI 0.23–4.86; P=0.94), transfusion (aOR 0.86; 95% CI 0.63–1.17; P=0.32), 
repeat PCI (aOR 0.75; 95% CI 0.18–3.15; P=0.69), stent thrombosis (aOR 2.45; 95% CI 0.15–
39.7; P=0.53), and death (aOR 1.09; 95% CI 0.59–2.00; P=0.79). Of note, we did not evaluate 
the impact of these drugs among patients who underwent radial access PCI given the small 
number of events in this subgroup. 
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In a sensitivity analysis, we excluded 186 (14.8%) patients from the bivalirudin 
monotherapy group who also received procedural UFH (supplemental table S2). Consistent with 
the primary results, after matching, there were no significant differences in in-hospital outcomes 
between the two treatment groups (supplemental figure S1). 
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DISCUSSION 
 
 In this retrospective, multicenter, observational study examining patients on dialysis 
undergoing PCI, we compared the safety and effectiveness of bivalirudin monotherapy versus 
UFH monotherapy. To our knowledge, this is the largest multicenter study assessing the use of 
these two anticoagulation strategies in this high-risk population. The key finding from this study 
was the lack of significant differences in clinically important in-hospital outcomes between 
patients on dialysis who received bivalirudin monotherapy compared with UFH monotherapy.  
Consistent with prior research, we demonstrated that patients on dialysis experienced 
inferior outcomes after PCI compared with those not on dialysis, further highlighting the 
importance of understanding the nuances of peri-procedural treatment in this high-risk 
population (4,5,7,8,29). Given the lack of randomized controlled trials informing care, well-
designed observational studies are needed.  
 Numerous randomized controlled trials have demonstrated a reduction in bleeding events 
and non-inferiority for ischemic events associated with bivalirudin when compared to UFH plus 
GPI therapy (11-15). Furthermore, observational studies and post-hoc analyses of these trials 
have shown that the benefit of bivalirudin is preserved in CKD patients; however, as previously 
noted, these studies tended to exclude or underrepresent patients on dialysis (7,8,29,30).  
In 2010, Delhaye et al published a single-center retrospective analysis evaluating the 
safety and effectiveness of bivalirudin and UFH monotherapy in 396 dialysis-dependent patients 
who underwent PCI (21). Similar to our findings, they found no significant difference in clinical 
endpoints among patients treated with bivalirudin versus UFH. There are many potential reasons 
for this negative finding. First, unlike prior observational studies and randomized trials, we 
excluded patients who received a GPI from this analysis, given that GPI use in a provisional 
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manner may be associated with a high-risk subset of patients. As a recent meta-analysis suggests, 
the increased rates of bleeding seen with UFH in prior clinical trials comparing UFH and 
bivalirudin may be attributable to the GPI strategy used in these trials (31). Second, our findings 
are consistent with the recently published NAPLES III trial which demonstrated no significant 
difference in rates of major bleeding between bivalirudin and UFH among patients at increased 
risk of bleeding undergoing PCI (32). However, this trial also excluded patients with end-stage 
renal disease. 
Lastly, we did not collect information regarding the specific dose of administered 
anticoagulant drugs, nor do we have details regarding the relative timing of each patient’s 
subsequent dialysis session in relation to the timing of anticoagulant administration. Therefore, 
differences in medication dosages as well as the timing of dialysis could partially account for 
these findings (33). Nevertheless, after adjusting for known differences between patients 
receiving bivalirudin compared with UFH, these medications resulted in similar in-hospital 
safety and effectiveness profiles. This finding has important clinical and economic implications 
warranting further study, as UFH monotherapy is substantially less expensive than bivalirudin 
monotherapy (34). 
 
Limitations  
 The findings from this study should be interpreted with specific caveats. First, all 
hospitals participating in this registry are actively engaged in statewide collaborative quality 
improvement initiatives. Therefore, these findings may not be generalizable to hospitals that do 
not participate in such initiatives (35). Second, our findings represent associations, and should 
not be interpreted as implying causation. Third, as mentioned above, we did not collect data on 
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medication dosages, laboratory testing evaluating the effectiveness of anticoagulation (e.g., 
activated clotting time), or the timing of medication administration relative to the patient’s 
subsequent dialysis session. Furthermore, we were only able to examine short-term outcomes 
that occurred during the incident hospitalization. Long-term outcomes may differ from these 
findings and warrants further investigation. Lastly, we do not know the reason behind the 
selection of specific antithrombotic medications. The rationale for the use of these drugs may be 
associated with higher or lower risk subgroups, though we attempted to minimize bias using 
optimal full matching. 
 
Conclusions 
 We demonstrated similar safety and effectiveness of bivalirudin monotherapy compared 
with UFH monotherapy among dialysis patients who underwent PCI. Given the substantial cost 
difference between UFH and bivalirudin monotherapy (34), and in the absence of randomized 
data to the contrary, our findings suggest that UFH monotherapy may be a safe and potentially 
cost-effective anticoagulant strategy in this high-risk subgroup of patients undergoing PCI. 
Further evaluation of this anticoagulant regimen in patients on dialysis is needed.
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FIGURE LEGENDS 
Figure 1: In-hospital outcome rates before matching. 
Bar graph demonstrating in-hospital outcome rates prior to matching among dialysis patients 
receiving bivalirudin monotherapy compared with unfractionated heparin monotherapy. 
Abbreviations: UFH = unfractionated heparin; NCDR = National Cardiovascular Data 
Registry; PCI = percutaneous coronary intervention. 
 
 
Figure 2: Plot of absolute standardized differences before and after matching. 
Absolute standardized differences before and after matching in dialysis patients receiving 
bivalirudin compared with unfractionated heparin.  
Abbreviations: PCI = percutaneous coronary intervention; LV = left ventricular; PAD = 
peripheral artery disease; CVD = cerebrovascular disease; CABG = coronary artery bypass 
grafting; HF = heart failure; MI = myocardial infarction; CAD = coronary artery disease; 
STEMI = ST-segment elevation myocardial infarction; Sx = symptoms. 
 
 
Figure 3: Adjusted odds ratios of in-hospital outcomes in the matched cohort.   
Adjusted odds ratios with 95% confidence intervals displayed. Adjusted bivalirudin and UFH 
event rates presented on the right side of the figure. 
Abbreviations: UFH = unfractionated heparin; NCDR = National Cardiovascular Data 
Registry; PCI = percutaneous coronary intervention 
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Table 1: Baseline characteristics and outcomes of patients by dialysis use. 
 
Variable 
On dialysis 
(n=4,303) 
Not on dialysis 
(n=173,660) P value 
Demographics    
 Age (years) 65.23 ± 11.37 65.06 ± 12.04 0.35 
 Male gender 2,573/4,303 (59.8%) 115,853/173,658 (66.7%) < 0.001 
 Body mass index (kg/m
2
) 30.17 ± 8.73 30.62 ± 7.53 < 0.001 
 White race 2,708/4,303 (62.9%) 150,543/173,660 (86.7%) < 0.001 
 Black or African American 
race 1,460/4,303 (33.9%) 18,375/173,660 (10.6%) < 0.001 
    
Comorbidities    
 Current/recent smoker (within 
1 year) 837/4,299 (19.5%) 51,038/173,579 (29.4%) < 0.001 
 Hypertension 4,182/4,300 (97.3%) 147,813/173,600 (85.1%) < 0.001 
 Dyslipidemia 3,727/4,294 (86.8%) 142,400/173,505 (82.1%) < 0.001 
 Family history of premature 
CAD 586/4,301 (13.6%) 31,486/173,606 (18.1%) < 0.001 
 Prior MI 2,086/4,303 (48.5%) 60,363/173,626 (34.8%) < 0.001 
 Prior heart failure 2,301/4,301 (53.5%) 27,032/173,587 (15.6%) < 0.001 
 Prior valve surgery/procedure 131/4,298 (3.0%) 3,022/173,575 (1.7%) < 0.001 
 Prior PCI 2,311/4,303 (53.7%) 78,780/173,629 (45.4%) < 0.001 
 Prior CABG 1,035/4,302 (24.1%) 31,911/173,609 (18.4%) < 0.001 
 Cerebrovascular disease 1,347/4,298 (31.3%) 26,314/173,592 (15.2%) < 0.001 
 Peripheral arterial disease 1,655/4,300 (38.5%) 27,078/173,600 (15.6%) < 0.001 
 Chronic lung disease 1,242/4,299 (28.9%) 32,541/173,593 (18.7%) < 0.001 
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 Diabetes mellitus 3,143/4,303 (73.0%) 64,990/173,619 (37.4%) < 0.001 
 Heart failure within 2 Weeks 1,391/4,300 (32.3%) 18,587/173,586 (10.7%) < 0.001 
 Cardiomyopathy or left 
ventricular systolic dysfunction 948/4,302 (22.0%) 17,911/173,618 (10.3%) < 0.001 
 Cardiogenic shock within 24 
Hours 127/4,303 (3.0%) 3,069/173,610 (1.8%) < 0.001 
 Cardiac arrest within 24 Hours 84/4,303 (2.0%) 3,370/173,578 (1.9%) 0.96 
 Pre-PCI left ventricular 
ejection fraction (%) 47.45 ± 14.52 52.03 ± 12.76 < 0.001 
 Pre-procedure hemoglobin 
(g/dL) 10.76 ± 1.79 13.50 ± 1.88 < 0.001 
     
CAD Presentation    
 No symptom, no angina 336/4,303 (7.8%) 8,805/173,615 (5.1%) < 0.001 
 Symptom unlikely to be 
ischemic 121/4,303 (2.8%) 4,037/173,615 (2.3%) 0.037 
 Stable angina 412/4,303 (9.6%) 22,827/173,615 (13.1%) < 0.001 
 Unstable angina 1,687/4,303 (39.2%) 73,331/173,615 (42.2%) < 0.001 
 Non-STEMI 1,455/4,303 (33.8%) 36,673/173,615 (21.1%) < 0.001 
 STEMI or equivalent 292/4,303 (6.8%) 27,942/173,615 (16.1%) < 0.001 
     
P2Y12 Inhibitor Administration    
 Pre-procedural clopidogrel 1,992/4,303 (46.3%) 61,108/173,660 (35.2%) < 0.001 
 Pre-procedural prasugrel 93/4,303 (2.2%) 6,013/173,660 (3.5%) < 0.001 
 Pre-procedural ticagrelor* 51/2,134 (2.4%) 2,849/81,870 (3.5%) 0.006 
     
Procedural Characteristics    
 Intra-aortic balloon pump 124/4,301 (2.9%) 4,399/173,616 (2.5%) 0.15 
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 Other mechanical ventricular 
support 91/4,298 (2.1%) 1,471/173,586 (0.8%) < 0.001 
 Femoral artery access site 3,838/4,302 (89.2%) 138,287/173,621 (79.6%) < 0.001 
 Radial artery access site 438/4,302 (10.2%) 34,739/173,621 (20.0%) < 0.001 
 Cardiogenic Shock at Start of 
PCI 133/4,301 (3.1%) 3,578/173,543 (2.1%) < 0.001 
     
PCI Indication    
 Immediate PCI for STEMI 250/4,302 (5.8%) 25,043/173,617 (14.4%) < 0.001 
 PCI for STEMI (Unstable, >12 
hours from symptom onset) 28/4,302 (0.7%) 1,418/173,617 (0.8%) 0.23 
 PCI for STEMI (Stable, >12 
hours from symptom onset) 21/4,302 (0.5%) 451/173,617 (0.3%) 0.004 
 PCI for STEMI (Stable after 
successful full-dose 
thrombolysis) 1/4,302 (0.0%) 556/173,617 (0.3%) < 0.001 
 Rescue PCI for STEMI (after 
failed full-dose thrombolytics) 4/4,302 (0.1%) 906/173,617 (0.5%) < 0.001 
 PCI for high risk Non-STEMI 
or unstable angina 2,826/4,302 (65.7%) 98,409/173,617 (56.7%) < 0.001 
 Staged PCI 162/4,302 (3.8%) 7,525/173,617 (4.3%) 0.070 
 Other 1,010/4,302 (23.5%) 39,309/173,617 (22.6%) 0.196 
     
In-hospital Outcomes    
 Stent thrombosis 5/4,303 (0.1%) 328/173,660 (0.2%) 0.28 
 Repeat PCI 24/4,303 (0.6%) 724/173,660 (0.4%) 0.158 
 Major bleeding 23/3,911 (0.6%) 1,758/144,904 (1.2%) < 0.001 
 Blood transfusion 510/4,299 (11.9%) 4,745/173,563 (2.7%) < 0.001 
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 NCDR bleeding 189/4,299 (4.4%) 4,852/173,560 (2.8%) < 0.001 
 Death 151/4,303 (3.5%) 2,523/173,660 (1.5%) < 0.001 
 
Data are presented as n/N (%) or mean ± standard deviation where appropriate. 
* Data on ticagrelor administration was collected beginning on January 1, 2013. 
Abbreviations: CAD = coronary artery disease; MI = myocardial infarction; PCI = percutaneous coronary 
intervention; CABG = coronary artery bypass grafting; STEMI = ST-segment elevation myocardial infarction; 
IABP = intra-aortic balloon pump; NCDR = National Cardiovascular Data Registry.  
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Table 2: Baseline characteristics of dialysis patients receiving bivalirudin monotherapy versus unfractionated heparin monotherapy 
before and after matching.  
 
    Before matching After matching 
  
Heparin 
(n=2,112) 
Bivalirudin 
(n=1,257) 
Standardized 
difference (%)  P value   
Heparin 
(n=2,112) 
Bivalirudin 
(n=1,257) 
Standardized 
difference (%)  P value 
Demographics 
  Age (years) 65.6±10.9 65.2±11.9 -2.8% 0.44 65.2 65.4 2.0% 0.61 
  Male 61.2% 59.2% 4.0% 0.27 61.0% 60.1% 1.7% 0.66 
  Body mass index (kg/m
2
) 29.9±8.2 30.4±8.9 5.2% 0.15 30.1 30.2 1.0% 0.78 
  White race 56.7% 73.3% 34.9% < 0.001 68.7% 68.7% 0.0% 1.00 
  Black or African American race 39.8% 23.9% -34.1% < 0.001 28.4% 28.7% 0.5% 0.69 
    
Comorbidities 
  
Current/recent smoker (within 1 
year) 19.4% 19.1% -0.7% 0.85 19.3% 18.7% -1.5% 0.70 
  Hypertension 98.1% 97.6% -2.9% 0.42 97.8% 97.5% -2.1% 0.62 
  Dyslipidemia 87.9% 86.3% -4.8% 0.180 87.2% 87.0% -0.6% 0.87 
  Family history of premature CAD 12.0% 15.8% 11.2% 0.002 13.8% 14.1% 1.0% 0.79 
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  Prior MI 51.0% 47.8% -6.4% 0.075 49.3% 49.5% 0.3% 0.93 
  Prior heart failure 56.8% 52.4% -8.8% 0.014 53.9% 54.1% 0.4% 0.93 
  Prior valve surgery/procedure 3.4% 2.6% -4.6% 0.20 2.9% 3.0% 0.9% 0.82 
  Prior PCI 57.3% 52.0% -10.5% 0.003 55.6% 55.3% -0.7% 0.86 
  Prior CABG 23.2% 27.6% 10.2% 0.005 25.9% 26.6% 1.7% 0.67 
  Cerebrovascular disease 32.3% 31.3% -2.2% 0.54 31.1% 31.5% 1.0% 0.81 
  Peripheral arterial disease 39.8% 37.4% -5.1% 0.156 37.9% 38.4% 1.0% 0.80 
  Chronic lung disease 29.5% 29.7% 0.4% 0.92 29.2% 30.1% 1.8% 0.65 
  Diabetes mellitus 74.5% 72.4% -4.7% 0.191 73.4% 73.5% 0.3% 0.95 
  Heart failure within 2 weeks 34.5% 30.7% -8.0% 0.026 31.8% 31.3% -1.0% 0.80 
  
Cardiomyopathy or left 
ventricular systolic dysfunction 23.1% 20.8% -5.4% 0.134 21.6% 21.9% 0.6% 0.87 
  
Cardiogenic shock within 24 
hours 2.9% 1.7% -8.0% 0.026 1.0% 0.9% -0.9% 0.57 
  Cardiac arrest within 24 hours 1.8% 1.6% -1.6% 0.65 0.5% 0.5% 0.0% 1.00 
  
Pre-PCI left ventricular ejection 
fraction (%) 47.5±14.7 48.8±13.9 9.9% 0.006 48.7 48.6 -0.7% 0.86 
  Pre-procedure hemoglobin (g/dL) 10.5±1.7 10.9±1.8 19.8% < 0.001 10.7 10.7 0.0% 0.99 
    
CAD Presentation/Management 
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  No symptom, no angina 7.0% 9.6% 9.4% 0.009 8.2% 8.2% 0.0% 1.00 
  Symptom unlikely to be ischemic 2.5% 3.3% 4.9% 0.175 2.9% 2.9% 0.0% 1.00 
  Stable angina 8.7% 12.2% 12.0% 0.001 10.7% 10.7% 0.0% 1.00 
  Unstable angina 42.1% 37.5% -9.4% 0.009 40.6% 40.6% 0.0% 1.00 
  Non-STEMI 35.3% 32.3% -6.4% 0.074 33.7% 33.7% 0.0% 1.00 
  STEMI or equivalent 4.4% 5.1% 3.3% 0.35 4.0% 4.0% 0.0% 1.00 
           
P2Y12 Inhibitor Administration          
 Pre-procedural clopidogrel 49.8% 44.7% -10.3% 0.004  48.5% 46.2% -4.5% 0.26 
 Pre-procedural prasugrel 2.0% 1.8% -1.5% 0.69  1.7% 2.1% 2.8% 0.49 
 Pre-procedural ticagrelor* 1.6% 0.8% -7.3% 0.043  1.3% 0.6% -6.2% 0.093 
           
Procedural Characteristics 
  IABP 3.1% 1.5% -10.8% 0.003 0.9% 1.1% 1.7% 0.23 
  
Other mechanical ventricular 
support 2.8% 0.8% -13.8% < 0.001 0.9% 0.6% -1.9% 0.23 
  Femoral artery access site 87.7% 90.3% 8.1% 0.025 85.8% 89.9% 13.0% 0.002 
  Radial artery access site 11.7% 9.2% -8.1% 0.025 13.5% 9.6% -12.8% 0.002 
  Cardiogenic shock at start of PCI 3.3% 1.6% -10.4% 0.004 1.1% 1.2% 0.7% 0.54 
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PCI Indication 
  Immediate PCI for STEMI 3.5% 4.5% 5.5% 0.128 3.5% 3.5% -0.1% 0.96 
  
PCI for STEMI (Unstable, >12 
hours from symptom onset) 0.7% 0.5% -2.5% 0.49 0.5% 0.5% 0.1% 0.96 
  
PCI for STEMI (Stable, >12 hours 
from symptom onset) 0.4% 0.1% -6.4% 0.073 0.0% 0.0% 0.0% 1.00 
  
PCI for STEMI (Stable after 
successful full-dose thrombolysis) 0.0% 0.1% 4.7% 0.195 0.0% 0.0% 0.0% 1.00 
  
Rescue PCI for STEMI (after 
failed full-dose thrombolytic) 0.1% 0.0% -3.9% 0.28 0.0% 0.0% 0.0% 1.00 
  
PCI for high risk Non-STEMI or 
unstable angina 69.5% 64.5% -10.7% 0.003 67.7% 67.3% -0.8% 0.73 
  Staged PCI 4.2% 4.4% 1.1% 0.76 4.2% 4.3% 0.2% 0.97 
  Other 21.7% 25.9% 10.1% 0.005 24.1% 24.5% 0.8% 0.76 
 
 
Data are presented as percentages (%) or means ± standard deviations where appropriate. 
* Data on ticagrelor administration was collected beginning on January 1, 2013. 
Abbreviations: CAD = coronary artery disease; MI = myocardial infarction; PCI = percutaneous coronary intervention; CABG = coronary artery bypass 
grafting; STEMI = ST-segment elevation myocardial infarction; IABP = intra-aortic balloon pump.  
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Figure 1: In-hospital outcome rates before matching.  
Bar graph demonstrating in-hospital outcome rates prior to matching among dialysis patients receiving 
bivalirudin monotherapy compared with unfractionated heparin monotherapy.  
Abbreviations: UFH = unfractionated heparin; NCDR = National Cardiovascular Data Registry; PCI = 
percutaneous coronary intervention.  
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Figure 2: Plot of absolute standardized differences before and after matching.  
Absolute standardized differences before and after matching in dialysis patients receiving bivalirudin 
compared with unfractionated heparin.  
Abbreviations: PCI = percutaneous coronary intervention; LV = left ventricular; PAD = peripheral artery 
disease; CVD = cerebrovascular disease; CABG = coronary artery bypass grafting; HF = heart failure; MI = 
myocardial infarction; CAD = coronary artery disease; STEMI = ST-segment elevation myocardial infarction; 
Sx = symptoms.  
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Figure 3: Adjusted odds ratios of in-hospital outcomes in the matched cohort.    
Adjusted odds ratios with 95% confidence intervals displayed. Adjusted bivalirudin and UFH event rates 
presented on the right side of the figure.  
Abbreviations: UFH = unfractionated heparin; NCDR = National Cardiovascular Data Registry; PCI = 
percutaneous coronary intervention  
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Supplementary Material 
 
Table S1: List of covariates included in the propensity score models. 
 
Table S2: Baseline characteristics of dialysis patients receiving bivalirudin monotherapy versus 
unfractionated heparin monotherapy before and after matching in the sensitivity analysis cohort. 
 
Figure S1: Adjusted odds ratios and event rates of in-hospital outcomes in the matched 
sensitivity analysis cohort
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2 
• Age 
• Gender  
• Race (White*, Black, Asian, other) 
• CAD presentation (STEMI, NSTEMI, unstable angina, stable angina, non-ischemic, no 
symptoms)* 
• PCI status (elective, urgent, emergency, salvage) 
• PCI indication (primary PCI, PCI for STEMI > 12 hours post-symptom onset, PCI for 
STEMI after successful or failed thrombolytic therapy, PCI for high risk NSTEMI or 
unstable angina, staged PCI, other) 
• Current or recent smoker (within 1 year) 
• Hypertension 
• Dyslipidemia 
• Family history of premature CAD 
• Prior myocardial infarction 
• Prior heart failure 
• Prior valve surgery/procedure 
• Prior PCI 
• Prior coronary artery bypass grafting 
• Admission source (emergency department, transfer, other) 
• Height 
• Weight 
• Cerebrovascular disease 
• Peripheral arterial disease 
• Chronic lung disease 
• Diabetes mellitus 
• Heart failure within 2 weeks 
• Cardiomyopathy or left ventricular systolic dysfunction 
• Cardiogenic shock within 24 hours* 
• Cardiogenic shock at start of PCI* 
• Cardiac arrest within 24 hours* 
• Pre-procedure hemoglobin 
• Use of intra-aortic balloon pump or other mechanical ventricular support device* 
 
* Exact matching required for CAD presentation, white race, cardiogenic shock within 24 hours or at the start of 
PCI, cardiac arrest, and use of intra-aortic balloon pump or other mechanical ventricular support device 
 
Abbreviations: CAD, coronary artery disease; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-
ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention.
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Table S2: Baseline characteristics of dialysis patients receiving bivalirudin monotherapy versus unfractionated heparin monotherapy 
before and after matching in the sensitivity analysis cohort. 
 
3 
    Before matching After matching 
  
Heparin 
(n=2,112) 
Bivalirudin 
(n=1,071) 
Standardized 
difference (%)  P value   
Heparin 
(n=2,112) 
Bivalirudin 
(n=1,071) 
Standardized 
difference (%)  
P 
Value 
Demographics 
  Age (years) 65.6±10.9 65.1±12.0 -4.2% 0.271 
 
65.5 65.5 -0.2% 0.954 
  Male 61.2% 58.9% 4.6% 0.223 
 
60.2% 59.2% 1.9% 0.640 
  Body mass index (kg/m
2
) 29.9±8.2 30.4±9.1 5.4% 0.156 
 
30.3 30.3 -0.3% 0.930 
  White race 56.7% 74.1% 36.4% < 0.001 
 
69.6% 69.6% 0.0% 1.000 
  Black or African American race 39.8% 22.9% -36.3% < 0.001 
 
27.2% 27.9% 1.7% 0.210 
    
        
Comorbidities 
        
  
Current/recent smoker (within 1 
year) 
19.4% 19.0% -1.1% 0.779 
 
18.7% 18.5% -0.5% 
0.916 
  Hypertension 98.1% 97.7% -2.5% 0.511 
 
98.0% 97.7% -1.7% 0.686 
  Dyslipidemia 87.9% 85.9% -6.1% 0.110 
 
87.0% 86.3% -2.0% 0.639 
  
Family history of premature 
CAD 
12.0% 15.3% 9.9% 0.009 
 
14.4% 13.6% -2.3% 
0.591 
  Prior MI 51.0% 48.6% -4.8% 0.206 
 
49.5% 50.2% 1.5% 0.727 
  Prior heart failure 56.8% 52.3% -9.0% 0.017 
 
54.2% 54.1% -0.1% 0.980 
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Table S2: Baseline characteristics of dialysis patients receiving bivalirudin monotherapy versus unfractionated heparin monotherapy 
before and after matching in the sensitivity analysis cohort (continued). 
 
4 
  Prior valve surgery/procedure 3.4% 2.7% -4.1% 0.279 
 
2.9% 3.1% 0.9% 0.819 
  Prior PCI 57.3% 53.1% -8.4% 0.027 
 
55.9% 55.3% -1.1% 0.782 
  Prior CABG 23.2% 27.8% 10.8% 0.004 
 
28.1% 27.2% -2.0% 0.636 
  Cerebrovascular disease 32.3% 31.4% -2.0% 0.596 
 
31.1% 31.4% 0.5% 0.898 
  Peripheral arterial disease 39.8% 37.9% -3.9% 0.304 
 
39.1% 38.0% -2.4% 0.569 
  Chronic lung disease 29.5% 30.0% 1.2% 0.759 
 
29.9% 30.2% 0.7% 0.875 
  Diabetes mellitus 74.5% 73.5% -2.3% 0.540 
 
75.1% 74.2% -2.2% 0.611 
  Heart failure within 2 weeks 34.5% 31.2% -7.0% 0.064 
 
31.5% 31.7% 0.3% 0.933 
  
Cardiomyopathy or left 
ventricular systolic dysfunction 
23.1% 20.4% -6.4% 0.091 
 
21.2% 21.1% -0.3% 
0.945 
  
Cardiogenic shock within 24 
hours 
2.9% 1.6% -8.5% 0.025 
 
1.0% 0.7% -1.7% 
0.291 
  Cardiac arrest within 24 hours 1.8% 1.8% -0.2% 0.959 
 
0.6% 0.6% 0.0% 1.000 
  
Pre-PCI left ventricular ejection 
fraction (%) 
47.5±14.7 49.0±13.8 11.0% 0.004 
 
48.7 48.9 1.8% 
0.639 
  
Pre-procedure hemoglobin 
(g/dL) 
10.5±1.7 10.9±1.8 18.6% < 0.001 
 
10.8 10.8 0.2% 
0.958 
    
        
CAD Presentation 
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Table S2: Baseline characteristics of dialysis patients receiving bivalirudin monotherapy versus unfractionated heparin monotherapy 
before and after matching in the sensitivity analysis cohort (continued). 
 
5 
  No symptom, no angina 7.0% 9.7% 10.0% 0.008 
 
8.7% 8.7% 0.0% 1.000 
  
Symptom unlikely to be 
ischemic 
2.5% 3.5% 6.1% 0.109 
 
3.1% 3.1% 0.0% 
1.000 
  Stable angina 8.7% 12.0% 11.3% 0.003 
 
10.8% 10.8% 0.0% 1.000 
  Unstable angina 42.1% 36.3% -11.8% 0.002 
 
39.0% 39.0% 0.0% 1.000 
  Non-STEMI 35.3% 33.3% -4.3% 0.260 
 
34.5% 34.5% 0.0% 1.000 
  STEMI or equivalent 4.4% 5.1% 3.5% 0.349 
 
3.9% 3.9% 0.0% 1.000 
    
        
Procedural Characteristics 
        
  IABP 3.1% 1.1% -12.9% 0.001 
 
0.5% 0.8% 1.7% 0.289 
  
Other mechanical ventricular 
support 
2.8% 0.8% -14.0% 0.000 
 
0.5% 0.2% -2.2% 
0.216 
  Femoral artery access site 87.7% 95.1% 25.1% 0.000 
 
86.8% 95.4% 29.0% 0.000 
  Radial artery access site 11.7% 4.3% -25.7% 0.000 
 
12.7% 4.3% -29.3% 0.000 
  
Cardiogenic shock at start of 
PCI 
3.3% 1.6% -10.2% 0.007 
 
0.8% 1.0% 1.2% 
0.342 
    
        
PCI Indication 
        
  Immediate PCI for STEMI 3.5% 4.7% 6.2% 0.104 
 
3.4% 3.5% 0.4% 0.685 
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Table S2: Baseline characteristics of dialysis patients receiving bivalirudin monotherapy versus unfractionated heparin monotherapy 
before and after matching in the sensitivity analysis cohort (continued). 
 
6 
  
PCI for STEMI (Unstable, >12 
hours from symptom onset) 
0.7% 0.4% -3.9% 0.303 
 
0.5% 0.4% -0.6% 
0.822 
  
PCI for STEMI (Stable, >12 
hours from symptom onset) 
0.4% 0.1% -6.0% 0.113 
 
0.0% 0.0% -0.7% 
0.617 
  
PCI for STEMI (Stable after 
successful full-dose 
thrombolysis) 
0.0% 0.1% 5.3% 0.160 
 
0.0% 0.0% 0.0% 
1.000 
  
Rescue PCI for STEMI (after 
failed full-dose thrombolytic) 
0.1% 0.0% -3.8% 0.314 
 
0.0% 0.0% 0.0% 
1.000 
  
PCI for high risk Non-STEMI 
or unstable angina 
69.5% 64.5% -10.6% 0.005 
 
66.7% 66.9% 0.3% 
0.898 
  Staged PCI 4.2% 4.5% 1.6% 0.674 
 
4.5% 4.5% 0.3% 0.948 
  Other 21.7% 25.7% 9.7% 0.011 
 
24.8% 24.6% -0.5% 0.867 
 
Data are presented as percentages (%) or means ± standard deviation where appropriate. 
Abbreviations: CAD = coronary artery disease; MI = myocardial infarction; PCI = percutaneous coronary intervention; CABG = coronary artery bypass 
grafting; STEMI = ST-segment elevation myocardial infarction; IABP = intra-aortic balloon pump. 
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Figure S1: Adjusted odds ratios and event rates of in-hospital outcomes in the matched 
sensitivity analysis cohort 
7 
 
 
 
Adjusted odds ratios with 95% confidence intervals displayed. Adjusted bivalirudin and UFH 
event rates are presented on the right side of the figure. 
Abbreviations: UFH = unfractionated heparin; NCDR = National Cardiovascular Data 
Registry; PCI = percutaneous coronary intervention 
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January 6, 2017  
 
Dr. Hitinder S. Gurm, MD  
University of Michigan Health System  
Department of Internal Medicine  
A. Alfred Taubman Health Care Center 
1500 East Medical Center Drive, Room TC B1 226  
Ann Arbor, Michigan 48109-0311  
 
RE: CIRCCVINT/2016/004835  
The Comparative Safety and Efficacy of Bivalirudin Versus Heparin Monotherapy in Patients on 
Dialysis Undergoing Percutaneous Coronary Intervention: Insights from the Blue Cross Blue 
Shield of Michigan Cardiovascular Consortium (BMC2)  
 
Dear Dr. Gurm,  
 
Thank you for your submission to Circulation: Cardiovascular Interventions. Although the 
editors found your manuscript to be well done and of considerable interest, your manuscript did 
not reach a priority sufficient for publication in Circulation: Cardiovascular Interventions. 
Nonetheless, we would like to encourage you to revise your manuscript for consideration for 
publication in the American Heart Association's new open access journal, JAHA: Journal of the 
American Heart Association.  
 
The reviews sent to you with this decision letter will serve as the initial evaluation for JAHA. If 
you wish to have your manuscript considered for publication in JAHA, please revise your paper 
in accordance with the reviewers' suggestions. A successful revision for JAHA will need to 
address the concerns of Reviewer 2.  
 
With your response to comments, please provide each comment verbatim in bold followed by 
your response. If substantive changes have been made to the manuscript, please provide a clear 
description of what you did and where. If you insert important sentences, paragraphs or sections 
in response to the comments, please include them in this response. Please also be clear about any 
deletions. Additionally, a marked-up version of the revision with the changes highlighted or 
tracked should be uploaded as a supplemental file. Please also refer to the Instructions to Authors 
for submitting a revision to JAHA.  
 
To initiate the transfer of your manuscript, you must go to: https://circinterventions-submit.aha-
journals.org/cgi-
bin/main.plex?el=A3Hr4BxQo5A3Rjr5X7A9ftd0XrE9faytxP6NHwikQWQgwZ.  
 
You will then receive a letter from JAHA with a link to submit your revised version or you can 
go to http://jaha-submit.aha-journals.org. JAHA's current guidelines allow 60 days for 
resubmission. If your resubmission to JAHA is not received within that timeframe, your 
manuscript record will close, and your paper will be considered as withdrawn from future 
consideration.  
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Please note that, if accepted, the following publication charges will apply:  
 
• Direct submissions: $2300  
• For authors referred with their peer-review reports from another AHA journal: $1700  
• For authors who are members of the American Heart Association (direct or referred 
submission): $1600  
 
Thank you very much for submitting your paper to Circulation: Cardiovascular Interventions. 
We hope you that you will submit a revised version to JAHA: Journal of the American Heart 
Association.  
 
Sincerely yours,  
 
Barry London, MD, PhD  
Editor-in-Chief  
JAHA: Journal of the American Heart Association  
 
David P. Faxon, MD  
Editor  
Circulation: Cardiovascular Interventions 
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Reviewer #1:  
 
Sukul D. et al. report a study evaluating the comparative safety and efficacy of bivalirudin 
monotherapy as compared to unfractionated heparin (UFH) monotherapy in dialysis 
patients undergoing percutaneous coronary intervention (PCI). The Authors included 
dialysis patients who underwent PCI in a multicenter registry between January 2010 and 
September 2015 at 47 Michigan hospitals. They compared in-hospital outcomes between 
bivalirudin versus UFH; excluding those treated with glycoprotein IIb/IIIa inhibitors. 
Optimal full matching was used to account for the non-random use of these drugs. Of 
177,963 patients who underwent PCI, 4,303 (2.4%) were on dialysis. Among those, 1,257 
(29.2%) received bivalirudin monotherapy and 2,112 (49.1%) received UFH monotherapy. 
Patients treated with bivalirudin had fewer comorbidities. After matching, there were no 
significant differences in outcomes between those who received bivalirudin versus UFH: 
bleeding (adjusted odds ratio: 0.67; 95% confidence interval: 0.41-1.07; P=0.093); major 
bleeding (0.81; 0.19-3.50; P=0.77); transfusion (1.01; 0.77-1.33; P=0.96); repeat PCI (0.57; 
0.14-2.24; P=0.42); stent thrombosis (0.56; 0.05-5.83; P=0.63); and death (0.84; 0.46-1.51; 
P=0.55). The Authors conclude that no significant differences exist in in-hospital outcomes 
between bivalirudin and UFH monotherapy in dialysis patients undergoing PCI.  
 
 
I have the following comments that may improve the clinical relevance of this study:  
 
1) In the Study Limitations, the Authors state that "we did not collect data on medication 
dosages or the timing of medication administration relative to the patient's subsequent 
dialysis session". Bivalirudin administration is usually contraindicated in patients with 
end-stage CKD and /or on dialysis. Dose adjustment is also recommended in patients with 
GFR>30 mL7min/1.732. The Authors should at least report in the METHODS section the 
policy of bivalirudin dose in patients in this subset of patients.  
 
We thank the Reviewer for highlighting this important issue. Although dosages adjustments for 
bivalirudin are recommended among patients with renal impairment, it is not contraindicated in 
dialysis.(1) The drug’s prescriber information states that the bolus dose does not need to be 
reduced for any degree of renal impairment. Furthermore, the infusion dose should be reduced to 
1.75 mg/kg/h for patients with a GFR of 30-59 mL/min; 1 mg/kg/h for patients with a GFR of 
<30 mL/min; and 0.25 mg/kg/h for patients on hemodialysis (1,2). 
 
The Blue Cross Blue Shield of Michigan Cardiovascular Collaborative (BMC2) PCI registry 
does not routinely collect drug dosing information; therefore, we were unable to account for 
variations in the dosages administered of either bivalirudin or unfractionated heparin (UFH). We 
also do not have information regarding each institution’s policy regarding UFH and bivalirudin 
dosing in patients on dialysis. However, since all hospitals in this study are actively engaged in 
statewide quality improvement initiatives through BMC2, there is an ongoing focus on ensuring 
optimal use of drugs and devices.  
 
As requested, we have added a sentence reporting the lack of medication dosage information 
(page 6, line 17). 
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“The BMC2 PCI registry does not routinely collect the dosages of bivalirudin or UFH 
administered during PCI.” 
 
 
2) The same concept is for unfractionated heparin (UFH) administration. The Authors 
should at least report in the METHODS section the policy of UFH dose in patients in this 
subset of patients.  
 
As noted above, we were unable to account for institution-specific dosing policies for UFH or 
bivalirudin. Notably, unfractionated heparin is primarily metabolized by the liver and 
endothelium, thus no dosage adjustment is required in patients on dialysis (2). 
 
 
3) In the study limitation, the Authors should acknowledge the lack of data on ACT value 
in the 2 groups of patients.  
 
We appreciate the Reviewer bringing this point to our attention. We have revised the following 
sentence to highlight the lack of this data (page 13, line 23). 
 
“Third, as mentioned above, we did not collect data on medication dosages, laboratory testing 
evaluating the efficacy of anticoagulation (e.g., activated clotting time), or the timing of 
medication administration relative to the patient’s subsequent dialysis session.” 
 
 
4) After matching, radial approach was higher in the dialysis group. This may represent a 
clinically relevant bias.  
 
We are unsure of the intended meaning behind the Reviewer’s comment as we did not match 
patients by dialysis status. Instead, among patients on dialysis undergoing PCI we matched 
patients who received bivalirudin monotherapy to those who received heparin monotherapy. The 
Reviewer may have meant to state, “After matching, radial approach was higher in the UFH 
group.” If this is the case, we answer this question more completely in response to comment #2 
by Reviewer #2 (see below). 
 
 
5) Please add the study by Shahzad et al. (Lancet. 2014 Nov 22;384(9957):1849-5 and 
Briguori et al. (JACC Cardiovasc Interv. 2015 Mar;8(3):414-23) in the discussion.  
 
The study by Shahzad et. al. was already included as reference #19. I have added the findings 
from the NAPLES III trial published by Briguori et al. (page 13, line 3): 
 
“Second, our findings are consistent with the recently published NAPLES III trial which 
demonstrated no significant difference in rates of major bleeding between bivalirudin and UFH 
among patients at increased risk of bleeding undergoing PCI (32). However, this trial also 
excluded patients with end-stage renal disease.” 
Page 45 of 72
Catheterization and Cardiovascular Interventions
Catheterization and Cardiovascular Interventions
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 5
Reviewer #2:  
 
In general, this is a well-done retrospective study attempting to report on differences in 
PCI outcomes in dialysis patients treated with heparin monotherapy or bivalirudin.  
 
1) A key missing component from the dataset is the dose of bivalirudin used. In the setting 
of dialysis dependency, the dose of bivalirudin is recommended to be decreased from the 
standard 1.75 mg/kg/h to 0.25 mg/kg/h. Was this done? I would imagine that there would 
be no way of knowing the patient-level data in this type of system-wide analysis. If dose 
adjustment was not performed, the impact on bleeding would likely be significant.  
 
Although patient-level data was used in this analysis, as previously noted, the BMC2 PCI 
registry does not routinely collect data regarding the dose of anticoagulant administered. The 
impact of drug dose and timing of dialysis relative to drug administration may have an important 
impact on post-procedural outcomes and should be an area of future investigation. We have 
identified this limitation (page 13, line 23). Nonetheless, our study provides insight into the 
effectiveness of these two anticoagulant strategies in real-world practice. We have also taken the 
liberty of changing the word efficacy to effectiveness in the title. 
 
“Third, as mentioned above, we did not collect data on medication dosages, laboratory testing 
evaluating the effectiveness of anticoagulation (e.g., activated clotting time), or the timing of 
medication administration relative to the patient’s subsequent dialysis session.” 
 
 
2) Femoral, as opposed to radial access PCI is subject to a greater frequency of bleeding. It 
appears from Table 2 that even after propensity score matching was performed, the 
bivalirudin patients had a significantly greater frequency of femoral PCI procedures. This 
likely would lead to more bleeding in bivalirudin-treated patients.  
 
We agree with the Reviewer and have performed further analysis to evaluate the effect of 
bivalirudin and UFH monotherapy among patients undergoing femoral access PCI. 
 
To evaluate the effect of chosen vascular access on the impact of bivalirudin vs. heparin on 
clinical outcomes we first assessed whether bivalirudin was significantly associated with 
vascular access choice after adjusting for clinical factors including: CAD presentation, PCI 
status, PCI indication, smoking, hypertension, dyslipidemia, family history of CAD, prior mi, 
prior heart failure, valve surgery, prior PCI, prior CABG, height, weight, prior cerebrovascular 
disease, prior peripheral artery disease, chronic lung disease, diabetes, heart failure within 2 
weeks, ejection fraction <40%, hemoglobin, race (white, black, Asian, other), admission source, 
left ventricular dysfunction, cardiogenic shock, and cardiac arrest. 
 
We found that bivalirudin monotherapy was significantly associated with a reduced likelihood of 
radial access (adjusted OR = 0.71; 95% CI: 0.56–0.91; P= 0.007) after adjusting for baseline 
covariates.  
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Given this significant association we pursued a stratified analysis evaluating the effect of 
bivalirudin vs. heparin on outcomes among patients who underwent femoral access PCI. Among 
patients undergoing femoral access PCI, there were no significant differences in the studied 
outcomes (see below).  
 
Outcome Adjusted Odds Ratio 95% Confidence Interval P value 
Bleeding 0.63 0.38 – 1.04 0.073 
Major bleeding 1.06 0.23 – 4.86 0.94 
Transfusion 0.86 0.63 – 1.17 0.32 
Repeat PCI 0.75 0.18 – 3.15 0.69 
Stent thrombosis 2.45 0.15 – 39.7 0.53 
Death 1.09 0.59 – 2.00 0.79 
Odds ratios greater than 1 are in favor of UFH monotherapy, whereas odds ratios less than 1 
are in favor of bivalirudin monotherapy. 
 
 
We have included these findings in the results section (page 10, line 9) as follows: 
 
“After matching, patients treated with bivalirudin monotherapy more frequently underwent 
femoral access PCI (89.9%) as compared with UFH monotherapy (85.8%; ASD 13.0%; 
P=0.002; Table 2). Due to this imbalance, we evaluated whether bivalirudin was significantly 
associated with vascular access site after adjusting for clinical factors. We found that bivalirudin 
monotherapy was significantly associated with a reduced likelihood of radial access (aOR 0.71; 
95% CI: 0.56–0.91; P=0.007). We then conducted a stratified analysis of bivalirudin 
monotherapy (n=1,144) versus UFH monotherapy (n=1,869) among patients who underwent 
femoral access PCI. Consistent with the overall findings, we found no significant differences in 
all studied outcomes including bleeding (aOR 0.63; 95% CI 0.38–1.04; P=0.073), major 
bleeding (aOR 1.06; 95% CI 0.23–4.86; P=0.94), transfusion (aOR 0.86; 95% CI 0.63–1.17; 
P=0.32), repeat PCI (aOR 0.75; 95% CI 0.18–3.15; P=0.69), stent thrombosis (aOR 2.45; 95% 
CI 0.15–39.7; P=0.53), and death (aOR 1.09; 95% CI 0.59–2.00; P=0.79). Of note, we did not 
evaluate the impact of these drugs among patients who underwent radial access PCI given the 
small number of events in this subgroup.” 
  
 
 
3) Examination of Figure 3 and other data in the manuscript suggest that virtually all odds 
ratios are in favor of bivalirudin treatment with a lack of significant p values because of the 
relatively small sample size. This would, of course, be at odds with the stated conclusions. 
 
We appreciate the Reviewer’s comments and have revised our stated conclusions (page 14, line 
12). 
 
“Given the substantial cost difference between UFH and bivalirudin monotherapy (34), and in 
the absence of randomized data to the contrary, our findings suggest that UFH monotherapy 
may be a safe and potentially cost-effective anticoagulant strategy in this high-risk subgroup of 
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patients undergoing PCI. Further evaluation of this anticoagulant regimen in patients on 
dialysis is needed.”  
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ABSTRACT 
Background:  
Dialysis patients are at a higher risk of bleeding after PCI; however, due to their exclusion from 
randomized clinical trials, the optimal antithrombotic regimen for this population remains 
unknown. We sought to evaluate the comparative safety and effectiveness of bivalirudin 
monotherapy versus unfractionated heparin (UFH) monotherapy in dialysis patients undergoing 
percutaneous coronary intervention (PCI). 
 
Methods:  
We included dialysis patients who underwent PCI in a multicenter registry between January 
2010 and September 2015 at 47 Michigan hospitals. We compared in-hospital outcomes between 
bivalirudin versus UFH; excluding those treated with glycoprotein IIb/IIIa inhibitors. Optimal 
full matching was used to account for the non-random use of these drugs. 
 
Results:  
Of 177,963 patients who underwent PCI, 4,303 (2.4%) were on dialysis. Among those, 1,257 
(29.2%) received bivalirudin monotherapy and 2,112 (49.1%) received UFH monotherapy. 
Patients treated with bivalirudin had fewer comorbidities. After matching, there were no 
significant differences in outcomes between those who received bivalirudin versus UFH: 
bleeding (adjusted odds ratio: 0.67; 95% confidence interval: 0.41–1.07; P=0.093); major 
bleeding (0.81; 0.19–3.50; P=0.77); transfusion (1.01; 0.77–1.33; P=0.96); repeat PCI (0.57; 
0.14–2.24; P=0.42); stent thrombosis (0.56; 0.05–5.83; P=0.63); and death (0.84; 0.46–1.51; 
P=0.55).  
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Conclusions:  
We found no significant differences in in-hospital outcomes between bivalirudin and UFH 
monotherapy among dialysis patients undergoing PCI. Randomized clinical trials are needed to 
determine the optimal anticoagulant regimen for this population. 
  
Word coun : 227 words (max 250 words) 
Keywords: Percutaneous coronary intervention; chronic kidney disease; anticoagulant; dialysis; 
outcomes. 
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ABBREVIATIONS 
CKD = chronic kidney disease 
PCI = percutaneous coronary intervention 
UFH = unfractionated heparin 
GPI = glycoprotein IIb/IIIa inhibitor 
BMC2 = Blue Cross Blue Shield of Michigan Cardiovascular Consortium 
NCDR = National Cardiovascular Data Registry 
CAD = coronary artery disease 
STEMI = ST-segment elevation myocardial infarction 
NSTEMI = non-ST-segment elevation myocardial infarction 
IABP = intra-aortic balloon pump 
aOR = adjusted odds ratio 
CI = confidence interval 
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INTRODUCTION 
 Patients on dialysis suffer death from cardiovascular causes at rates five to 30 times 
higher than the general population, making cardiovascular disease the leading cause of death in 
patients with end-stage renal disease (1). Chronic kidney disease (CKD) is associated with an 
increased risk of both bleeding and thrombosis due to multiple hemostatic perturbations (2,3). 
Furthermore, these patients experience increased rates of bleeding and reduced survival after 
percutaneous coronary intervention (PCI) when compared with patients without CKD (4-8). In 
fact, progressively worse outcomes after PCI are associated with increasingly severe stages of 
CKD, with the poorest outcomes occurring in patients on dialysis (5).  
 Despite this increased risk, patients on dialysis are underrepresented in, or excluded from 
important cardiovascular randomized controlled trials, resulting in a remarkable dearth of 
evidence to inform treatment in this high-risk population (9,10). Specifically, patients on dialysis 
have been underrepresented or excluded from trials evaluating the safety and effectiveness of 
unfractionated heparin (UFH) compared with bivalirudin (11-18). Many of these clinical trials 
demonstrated a reduction in bleeding complications without a significant difference in ischemic 
outcomes in patients treated with bivalirudin compared with UFH with or without glycoprotein 
IIb/IIIa inhibitors (GPIs) (11-16). Recently, studies have shown similar safety and effectiveness 
between bivalirudin monotherapy and UFH monotherapy in patients undergoing PCI, reigniting 
interest in UFH monotherapy as a more cost-effective treatment strategy (19,20). 
To our knowledge, there are few studies assessing the use of antithrombotic medications 
in dialysis patients undergoing PCI (21,22). Given the paucity of evidence, we sought to assess 
the comparative safety and effectiveness of bivalirudin monotherapy versus UFH monotherapy 
in dialysis patients undergoing PCI using a multicenter registry in the state of Michigan.  
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METHODS 
 
Study population 
We performed a retrospective analysis on data collected by the Blue Cross Blue Shield of 
Michigan Cardiovascular Consortium (BMC2), a regional registry of all patients undergoing PCI 
in the state of Michigan. A more detailed description of the registry, including data collection 
and auditing practices, has been described previously (23,24). Briefly, this is a prospective, 
multicenter, statewide registry of patients undergoing PCI at any non-federal hospital in 
Michigan. For the current study, we evaluated consecutive patients undergoing PCI between 
January 2010 and September 2015 at 47 hospitals. 
 
Study Groups 
We initially divided patients into two groups, those on dialysis and not on dialysis prior 
to PCI. Patients were considered to be on dialysis if they were undergoing either hemodialysis or 
peritoneal dialysis on an ongoing basis because of renal failure prior to PCI. To compare the 
safety and effectiveness of procedural bivalirudin and UFH, we stratified patients on dialysis by 
administration of these two drugs. The BMC2 PCI registry does not routinely collect the dosages 
of bivalirudin or UFH administered during PCI.  
We excluded patients who received procedural or pre-procedural low molecular weight 
heparin and/or fondaparinux as well as patients who had no recorded anticoagulant administered 
in the procedural time period. We also excluded patients who received a concomitant GPI, since 
GPI use is frequently restricted to higher risk anatomic subsets, or for bailout use secondary to 
suboptimal procedural results or complications. Of note, patients receiving procedural 
bivalirudin may have received pre-procedural UFH. Furthermore, a small fraction of patients 
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receiving procedural bivalirudin also had documented administration of procedural UFH (e.g. 
UFH is sometimes used during radial access cases). The impact of this subgroup on in-hospital 
outcomes was assessed in a sensitivity analysis excluding these patients. 
 
Study outcomes 
 All primary outcomes were measured during the incident hospitalization when PCI was 
performed. In-hospital outcomes included bleeding, presumed major bleeding, the need for 
transfusion, repeat PCI, stent thrombosis, and death due to any cause. Stent thrombosis was 
defined as thrombosis at the site of original stent placement demonstrated on repeat angiography. 
Repeat PCI was defined as repeat intervention during the incident hospitalization on the lesion 
that was initially treated. Bleeding, defined as per the National Cardiovascular Data Registry 
(NCDR), included an event within 72 hours of PCI that was associated with any of the 
following: a drop in hemoglobin ≥3 g/dL; transfusion of whole blood or packed red blood cells; 
an intervention or surgery at the site of bleeding to reverse, stop, or correct the bleeding (25). 
The need for transfusion was defined as the receipt of ≥1 unit of red blood cell or whole blood 
transfusion after PCI. Presumed major bleeding was defined as a decrease in baseline 
hemoglobin by >5 g/dL.  
 
Statistical analysis 
 Propensity scores were estimated using logistic regression models adjusting for baseline 
patient clinical and demographic variables (supplemental table 1). Optimal full matching was 
used to create matched patient strata constructed of patients generally similar in terms of baseline 
characteristics containing varying numbers of patients with (cases) and without (controls) the 
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covariate of interest (bivalirudin or UFH). As opposed to greedy matching, full matching allows 
treatment group members to share a control group member as long as it reduces the average 
distance between matches (26,27). Exact matching was required on coronary artery disease 
(CAD) presentation (ST-segment elevation myocardial infarction [STEMI], non-ST-segment 
elevation myocardial infarction [NSTEMI], unstable angina, stable angina, or other), race (white 
vs. non-white), cardiogenic shock within 24 hours prior to or at the start of PCI, use of an intra-
aortic balloon pump (IABP) or other mechanical ventricular support devices, and pre-procedural 
cardiac arrest. Stratified standardized differences using full match strata were used to assess the 
adequacy of the match in terms of covariate balance, with a threshold of 10% used to identify 
cases of substantial residual imbalance. Reported outcome rates were weighted by full match 
strata, and conditional logistic regression models accounting for matched patient strata were 
utilized to assess for independent association between procedural use of bivalirudin and UFH, 
and clinical outcomes. A similar full matching technique was used for the sensitivity analysis. 
All analyses were performed using R version 3.2.1 (28). 
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RESULTS 
Baseline characteristics 
 A total of 177,963 PCIs were performed between January 2010 and September 2015, of 
which 4,303 (2.4%) were on dialysis patients. The baseline characteristics of patients stratified 
by dialysis use are shown in Table 1. Generally, patients on dialysis had more comorbid 
conditions and experienced significantly worse outcomes after PCI, including increased rates of 
blood transfusions (11.9% vs. 2.7%; P < 0.001), NCDR bleeding (4.4% vs. 2.8%; P < 0.001), 
and death (3.5% vs. 1.5%; P < 0.001). Notably, patients on dialysis less frequently experienced 
major bleeding compared with patients not on dialysis (0.6% vs. 1.2%; P < 0.001).  
 Of the 4,303 patients on dialysis who underwent PCI, 109 (2.5%) received low molecular 
weight heparin, 13 (0.3%) received fondaparinux, 614 (14.3%) received a GPI, and 215 (5.0%) 
had no recor ed procedural anticoagulant. A total of 934 (2.3%) patients met at least one 
exclusion criteria, leaving 3,369 patients in the final cohort, of which 1,257 received bivalirudin 
monotherapy and 2,112 received UFH monotherapy. Patients receiving bivalirudin were more 
frequently white (73.3% vs. 56.7%; P < 0.001) and had fewer comorbid conditions (Table 2). 
They were also less likely to experience pre-procedural cardiogenic shock (1.7% vs. 2.9%, P = 
0.026), receive IABP support (1.5% vs. 3.1%, P = 0.003) or mechanical ventricular support 
(0.8% vs. 2.8%, P < 0.001) (Table 2).  Prior to matching, patients treated with bivalirudin 
monotherapy had lower rates of transfusion (8.7% vs. 11.9%; P = 0.003), bleeding (2.7% vs 
4.1%; P = 0.038), and in-hospital mortality (2.2% vs 3.4%; P = 0.051) after PCI compared with 
those treated with UFH monotherapy (Figure 1). 
Outcomes 
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After optimal full matching, the adjusted absolute standardized difference was <10% on 
all matched variables (Figure 2) with generally similar baseline characteristics within matched 
strata (Table 2). There were no significant differences in outcomes after adjusting for matched 
strata between patients treated with bivalirudin compared with UFH: bleeding (adjusted odds 
ratio [aOR] 0.67; 95% confidence interval [CI] 0.41–1.07; P=0.093); major bleeding (aOR 0.81; 
95% CI 0.19–3.50; P=0.77); transfusion (aOR 1.01; 95% CI 0.77–1.33; P=0.96); repeat PCI 
(aOR 0.57; 95% CI 0.14–2.24; P=0.42); stent thrombosis (aOR 0.56; 95% CI 0.05–5.83; 
P=0.63); and death (aOR 0.84; 95% CI 0.46–1.51; P=0.55) (Figure 3). 
After matching, patients treated with bivalirudin monotherapy more frequently underwent 
femoral access PCI (89.9%) compared with UFH monotherapy (85.8%; ASD 13.0%; P=0.002; 
Table 2). Due to this imbalance, we evaluated whether bivalirudin was significantly associated 
with vascular access site after adjusting for clinical factors. We found that bivalirudin 
monotherapy was significantly associated with a reduced likelihood of radial access (aOR 0.71; 
95% CI: 0.56–0.91; P=0.007). We then conducted a stratified analysis of bivalirudin 
monotherapy (n=1,144) versus UFH monotherapy (n=1,869) among patients who underwent 
femoral access PCI. Consistent with the overall findings, we found no significant differences in 
all studied outcomes including bleeding (aOR 0.63; 95% CI 0.38–1.04; P=0.073), major bleeding 
(aOR 1.06; 95% CI 0.23–4.86; P=0.94), transfusion (aOR 0.86; 95% CI 0.63–1.17; P=0.32), 
repeat PCI (aOR 0.75; 95% CI 0.18–3.15; P=0.69), stent thrombosis (aOR 2.45; 95% CI 0.15–
39.7; P=0.53), and death (aOR 1.09; 95% CI 0.59–2.00; P=0.79). Of note, we did not evaluate 
the impact of these drugs among patients who underwent radial access PCI given the small 
number of events in this subgroup. 
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In a sensitivity analysis, we excluded 186 (14.8%) patients from the bivalirudin 
monotherapy group who also received procedural UFH (supplemental table S2). Consistent with 
the primary results, after matching, there were no significant differences in in-hospital outcomes 
between the two treatment groups (supplemental figure S1). 
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DISCUSSION 
 
 In this retrospective, multicenter, observational study examining patients on dialysis 
undergoing PCI, we compared the safety and effectiveness of bivalirudin monotherapy versus 
UFH monotherapy. To our knowledge, this is the largest multicenter study assessing the use of 
these two anticoagulation strategies in this high-risk population. The key finding from this study 
was the lack of significant differences in clinically important in-hospital outcomes between 
patients on dialysis who received bivalirudin monotherapy compared with UFH monotherapy.  
Consistent with prior research, we demonstrated that patients on dialysis experienced 
inferior outcomes after PCI compared with those not on dialysis, further highlighting the 
importance of understanding the nuances of peri-procedural treatment in this high-risk 
population (4,5,7,8,29). Given the lack of randomized controlled trials informing care, well-
designed observational studies are needed.  
 Numerous randomized controlled trials have demonstrated a reduction in bleeding events 
and non-inferiority for ischemic events associated with bivalirudin when compared to UFH plus 
GPI therapy (11-15). Furthermore, observational studies and post-hoc analyses of these trials 
have shown that the benefit of bivalirudin is preserved in CKD patients; however, as previously 
noted, these studies tended to exclude or underrepresent patients on dialysis (7,8,29,30).  
In 2010, Delhaye et al published a single-center retrospective analysis evaluating the 
safety and effectiveness of bivalirudin and UFH monotherapy in 396 dialysis-dependent patients 
who underwent PCI (21). Similar to our findings, they found no significant difference in clinical 
endpoints among patients treated with bivalirudin versus UFH. There are many potential reasons 
for this negative finding. First, unlike prior observational studies and randomized trials, we 
excluded patients who received a GPI from this analysis, given that GPI use in a provisional 
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manner may be associated with a high-risk subset of patients. As a recent meta-analysis suggests, 
the increased rates of bleeding seen with UFH in prior clinical trials comparing UFH and 
bivalirudin may be attributable to the GPI strategy used in these trials (31). Second, our findings 
are consistent with the recently published NAPLES III trial which demonstrated no significant 
difference in rates of major bleeding between bivalirudin and UFH among patients at increased 
risk of bleeding undergoing PCI (32). However, this trial also excluded patients with end-stage 
renal disease. 
Lastly, we did not collect information regarding the specific dose of administered 
anticoagulant drugs, nor do we have details regarding the relative timing of each patient’s 
subsequent dialysis session in relation to the timing of anticoagulant administration. Therefore, 
differences in medication dosages as well as the timing of dialysis could partially account for 
these findings (33). Nevertheless, after adjusting for known differences between patients 
receiving bivalirudin compared with UFH, these medications resulted in similar in-hospital 
safety and effectiveness profiles. This finding has important clinical and economic implications 
warranting further study, as UFH monotherapy is substantially less expensive than bivalirudin 
monotherapy (34). 
 
Limitations  
 The findings from this study should be interpreted with specific caveats. First, all 
hospitals participating in this registry are actively engaged in statewide collaborative quality 
improvement initiatives. Therefore, these findings may not be generalizable to hospitals that do 
not participate in such initiatives (35). Second, our findings represent associations, and should 
not be interpreted as implying causation. Third, as mentioned above, we did not collect data on 
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medication dosages, laboratory testing evaluating the effectiveness of anticoagulation (e.g., 
activated clotting time), or the timing of medication administration relative to the patient’s 
subsequent dialysis session. Furthermore, we were only able to examine short-term outcomes 
that occurred during the incident hospitalization. Long-term outcomes may differ from these 
findings and warrants further investigation. Lastly, we do not know the reason behind the 
selection of specific antithrombotic medications. The rationale for the use of these drugs may be 
associated with higher or lower risk subgroups, though we attempted to minimize bias using 
optimal full matching. 
 
Conclusions 
 We demonstrated similar safety and effectiveness of bivalirudin monotherapy compared 
with UFH monotherapy among dialysis patients who underwent PCI. Given the substantial cost 
difference between UFH and bivalirudin monotherapy (34), and in the absence of randomized 
data to the contrary, our findings suggest that UFH monotherapy may be a safe and potentially 
cost-effective anticoagulant strategy in this high-risk subgroup of patients undergoing PCI. 
Further evaluation of this anticoagulant regimen in patients on dialysis is needed.
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FIGURE LEGENDS 
Figure 1: In-hospital outcome rates before matching. 
Bar graph demonstrating in-hospital outcome rates prior to matching among dialysis patients 
receiving bivalirudin monotherapy compared with unfractionated heparin monotherapy. 
Abbreviations: UFH = unfractionated heparin; NCDR = National Cardiovascular Data 
Registry; PCI = percutaneous coronary intervention. 
 
 
Figure 2: Plot of absolute standardized differences before and after matching. 
Absolute standardized differences before and after matching in dialysis patients receiving 
bivalirudin compared with unfractionated heparin.  
Abbreviations: PCI = percutaneous coronary intervention; LV = left ventricular; PAD = 
peripheral artery disease; CVD = cerebrovascular disease; CABG = coronary artery bypass 
grafting; HF = heart failure; MI = myocardial infarction; CAD = coronary artery disease; 
STEMI = ST-segment elevation myocardial infarction; Sx = symptoms. 
 
 
Figure 3: Adjusted odds ratios of in-hospital outcomes in the matched cohort.   
Adjusted odds ratios with 95% confidence intervals displayed. Adjusted bivalirudin and UFH 
event rates presented on the right side of the figure. 
Abbreviations: UFH = unfractionated heparin; NCDR = National Cardiovascular Data 
Registry; PCI = percutaneous coronary intervention 
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